Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Predictors, Risk Factors and Outcomes of Patients with SAA with Anti-HLA Class I Antibodies Treated with Immunosuppressive Therapy

Jibran Durrani, Leonard Chen, Ruba Shalhoub, Nu Ri Cha, Xiaoyang Ma, Jennifer Lotter, Olga Rios, Colin O. Wu, Willy A. Flegel, Neal S. Young, Bhavisha A. Patel, Emma M. Groarke

Blood (2022) 140 (Supplement 1): 77–78.

https://doi.org/10.1182/blood-2022-163442

Published: 2022

Journal Articles

Treatment of Refractory Diamond-Blackfan Anemia with Eltrombopag

Brynn B Duncan, Jennifer Lotter, Jeanine Superata, Ma Evette Barranta, Ivana Darden, Sanjay Venugopal, Colin O. Wu, Cynthia E. Dunbar, David J. Young

Blood (2022) 140 (Supplement 1): 5824–5825.

https://doi.org/10.1182/blood-2022-160297

Published: 2022

Journal Articles

The Role of Heterozygous Variants in SAMD9/9L and Recessive Bone Marrow Failure-Related Genes in Adults with Severe Aplastic Anemia

Dalton Hironaka, Xiaoyang Ma, Bhavisha A. Patel, Emma M. Groarke, Jennifer Lotter, Olga Rios, Juan L Coelho-Silva, Colin O. Wu, Jorg Cammenga, Fernanda Gutierrez-Rodrigues, Neal S. Young

Blood (2022) 140 (Supplement 1): 479–480.

https://doi.org/10.1182/blood-2022-162886

Published: 2022

Journal Articles

Alemtuzumab and Eltrombopag Combination for Patients with Refractory or Relapsed Severe Aplastic Anemia

Ash Lee Manley, Jennifer Lotter, Emma M. Groarke, Olga Rios, Neal S. Young, Bhavisha A. Patel

Blood (2022) 140 (Supplement 1): 10851–10852.

https://doi.org/10.1182/blood-2022-163825

Published: 2022

Journal Articles

Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study

Bhavisha A. Patel, Emma M. Groarke, Jennifer Lotter, Ruba Shalhoub, Fernanda Gutierrez-Rodrigues, Olga Rios, Diego Quinones Raffo, Colin O. Wu, Neal S. Young

Blood (2022) 139 (1): 34–43.

https://doi.org/10.1182/blood.2021012130

Published: 2022

Includes: Supplemental data

Journal Articles

Strong Predictors of Chromosomal Aberrations and Myeloid Neoplasia Following Immunosuppression Therapy for Severe Aplastic Anemia: A Retrospective Cohort Study

Emma M. Groarke, Bhavisha A. Patel, Ruba Shalhoub, Fernanda Gutierrez-Rodrigues, Parth Desai, Harshraj Leuva, Casey Paton, Nina Spitofsky, Jennifer Lotter, Olga Rios, Richard W. Childs, David J. Young, Alina Dulau-Florea, Cynthia E. Dunbar, Katherine R. Calvo, Colin O. Wu, Neal S. Young

Blood (2021) 138 (Supplement 1): 601.

https://doi.org/10.1182/blood-2021-146070

Published: 2021

Journal Articles

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

Christopher Pleyer, Kerry J Laing, Mir Ali, Christopher L McClurkan, Susan Soto, Inhye E. Ahn, Pia Nierman, Emeline Maddux, Jennifer Lotter, Jeanine Superata, Xin Tian, Erika M Gaglione, Adrian Wiestner, Jeffrey Cohen, David M Koelle, Clare Sun

Blood (2021) 138 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2021-148539

Published: 2021

Journal Articles

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Christopher Pleyer, Mir A. Ali, Jeffrey I. Cohen, Xin Tian, Susan Soto, Inhye E. Ahn, Erika M. Gaglione, Pia Nierman, Gerald E. Marti, Charles Hesdorffer, Jennifer Lotter, Jeanine Superata, Adrian Wiestner, Clare Sun

Blood (2021) 137 (2): 185–189.

https://doi.org/10.1182/blood.2020008758

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag

Emma M. Groarke, MD, Bhavisha A Patel, MD, Carrie Diamond, MD, Fernanda Gutierrez-Rodrigues, PhD, Alana Vicente, MD, Olga Rios, RN, Jennifer Lotter, PA-C, Daniela Baldoni, Ruba Shalhoub, Colin Wu, PhD, Neal S. Young, MD

Blood (2019) 134 (Supplement_1): 454.

https://doi.org/10.1182/blood-2019-124811

Published: 2019

Journal Articles

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Christopher Pleyer, MD, Jeffrey Cohen, MD, Susan Soto, Mir Ali, PhD, Inhye E Ahn, MD, Pia Nierman, BSN, MA, RN, Janet Valdez, Jennifer Lotter, PA-C, Jeanine Superata, RN, Xin Tian, Adrian Wiestner, MD PhD, Clare Sun, MD

Blood (2019) 134 (Supplement_1): 3053.

https://doi.org/10.1182/blood-2019-121675

Published: 2019

Journal Articles

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Blood (2019) 134 (Supplement_1): 5474.

https://doi.org/10.1182/blood-2019-126698

Published: 2019

Journal Articles

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Thomas Winkler, Xing Fan, James Cooper, Ronan Desmond, David J. Young, Danielle M. Townsley, Phillip Scheinberg, Sophia Grasmeder, Andre Larochelle, Marie Desierto, Janet Valdez, Jennifer Lotter, Colin Wu, Ruba N. Shalhoub, Katherine R. Calvo, Neal S. Young, Cynthia E. Dunbar

Blood (2019) 133 (24): 2575–2585.

https://doi.org/10.1182/blood.2019000478

Published: 2019

Journal Articles

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Xing Fan, MD, Thomas Winkler, MD, Ronan Desmond, MD, Bogdan Dumitriu, MD, Danielle M. Townsley, MD MSc, Maria del Pilar Fernandez Ibanez, Fernanda Gutierrez-Rodrigues, PhD, Sophia Grasmeder, RN, Ma Evette Barranta, Diane Madey, Jennifer Lotter, Janet Valdez, Katherine R. Calvo, MD PhD, Colin Wu, PhD, Neal S. Young, MD, Cynthia E. Dunbar, MD

Blood (2018) 132 (Supplement 1): 538.

https://doi.org/10.1182/blood-2018-99-112994

Published: 2018

Journal Articles

Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Christopher Pleyer, MD, Clare C. Sun, MD, Pia Niermann, Xin Tian, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Raquel Izumi, PhD, Ahmed Hamdy, MD, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2018-99-111919

Published: 2018

Journal Articles

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Clare C. Sun, MD, Pia Nierman, RN, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Susan Soto, Sarah E. M. Herman, PhD, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Dongmei Liu, PhD, Priti Patel, MD, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2018-99-110395

Published: 2018

Journal Articles

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Blood (2018) 131 (21): 2357–2366.

https://doi.org/10.1182/blood-2017-12-820910

Published: 2018

Includes: Supplemental data

Journal Articles

Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with CLL: A Pilot Phase II Study

Inhye E. Ahn, MD, Susan Soto, Pia Nierman, Xin Tian, PhD, Janet Valdez, Jennifer Lotter, Thomas Fleisher, Sergio Rosenzweig, Shakuntala Rampertaap, Irina Maric, Maryalice Stetler-Stevenson, Constance Yuan, Gerald Marti, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 3020.

https://doi.org/10.1182/blood.V130.Suppl_1.3020.3020

Published: 2017

Journal Articles

Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Thomas Winkler, MD, James N. Cooper, MD, Danielle M. Townsley, MDMSc, Phillip Scheinberg, MD, Sophia Grasmeder, RN, Colin Wu, PhD, Jennifer Lotter, Marie J Desierto, MS, Ronan Desmond, MD, Matthew J. Olnes, MD PhD, Katherine R Calvo, MD PhD, Neal S. Young, MD, Cynthia E Dunbar, MD

Blood (2017) 130 (Suppl_1): 777.

https://doi.org/10.1182/blood.V130.Suppl_1.777.777

Published: 2017

Journal Articles

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Inhye E. Ahn, MD, Xin Tian, PhD, Jennifer Lotter, Susan Soto, Janet Valdez, Pia Nierman, Maryalice stetler-Stevenson, Constance Yuan, Irina Maric, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 4302.

https://doi.org/10.1182/blood.V130.Suppl_1.4302.4302

Published: 2017

Journal Articles

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Blood (2017) 129 (11): 1469–1479.

https://doi.org/10.1182/blood-2016-06-719294

Published: 2017

Includes: Supplemental data

NARROW

Predictors, Risk Factors and Outcomes of Patients with SAA with Anti-HLA Class I Antibodies Treated with Immunosuppressive Therapy

Treatment of Refractory Diamond-Blackfan Anemia with Eltrombopag

The Role of Heterozygous Variants in SAMD9/9L and Recessive Bone Marrow Failure-Related Genes in Adults with Severe Aplastic Anemia

Alemtuzumab and Eltrombopag Combination for Patients with Refractory or Relapsed Severe Aplastic Anemia

Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study

Strong Predictors of Chromosomal Aberrations and Myeloid Neoplasia Following Immunosuppression Therapy for Severe Aplastic Anemia: A Retrospective Cohort Study

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Combination of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with CLL: A Pilot Phase II Study

Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only